爱博医疗（688050）：25Q2环比改善，隐形眼镜良率提升，高端新品放量可期

Investment Rating - The investment rating for the company is "Buy" [5] Core Views - The company reported a steady growth in revenue and profit in Q2 2025, with a revenue of 430 million yuan, up 14.44% year-on-year, and a net profit of 121 million yuan, up 14.85% year-on-year [1][2] - The company is experiencing improvements in the yield of contact lenses and is expected to see a ramp-up in high-end new products [2] - The gross margin decreased to 65.80% in Q2 2025, primarily due to the impact of centralized procurement policies and an increase in the proportion of low-margin contact lens products [2] Financial Performance - For H1 2025, the company achieved a revenue of 787 million yuan, a year-on-year increase of 14.72%, and a net profit of 213 million yuan, a year-on-year increase of 2.53% [1] - The revenue breakdown for H1 2025 includes contact lenses at 236 million yuan (up 28.89%), intraocular lenses at 345 million yuan (up 8.23%), and orthokeratology lenses at 119 million yuan (up 5.63%) [2] - The company’s domestic revenue reached 744 million yuan (up 12.37%), while overseas revenue surged to 43 million yuan (up 80.10%) [3] Market Position and Strategy - The company is enhancing its domestic sales channels and steadily advancing its overseas market layout, with a sales network covering over 6000 hospitals and vision centers across 31 provinces and municipalities in China [3] - The company has established a global sales network, exporting products to over 30 countries, including Germany, France, and the UK [3] - The company’s high-end products, such as the "All-View" multifocal intraocular lenses, are gaining rapid market acceptance, contributing to the growth of its product mix [2] Earnings Forecast - The company is projected to achieve revenues of 1.683 billion yuan, 2.112 billion yuan, and 2.662 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 19.4%, 25.5%, and 26.1% [4] - The forecasted net profits for the same years are 445 million yuan, 545 million yuan, and 667 million yuan, with growth rates of 14.7%, 22.4%, and 22.4% [4]